The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correction to Catalona, N Engl J Med 331(15):996-1004 October 13, 1994.

Correspondence
PreviousPrevious
Volume 332:335-336 February 2, 1995 Number 5
NextNext

Management of Cancer of the Prostate

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-Related Article
by Catalona, W. J.
-Related Article
by Catalona, W. J.
To the Editor: Dr. Catalona's article on the management of cancer of the prostate (Oct. 13 issue)1 was informative and thorough, except for two omissions concerning the treatment of patients with end-stage disease.

First, patients with extensive, painful bony metastases may benefit from treatment with strontium chloride labeled with strontium-89.2 This radionuclide is easily administered, is usually effective within a few weeks, and has beneficial effects that usually last for several months or more. The main disadvantages are cost and occasional thrombocytopenia. Although external-beam radiation therapy will remain the mainstay of treatment for the majority of patients with bony metastases, . . . [Full Text of this Article]

References



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.